Delta-Sleep Inducing Peptide (DSIP) is an amphiphilic nonapeptide widely evaluated in preclinical literature for its capacity to modulate slow-wave delta EEG rhythms and stress-axis signaling. For investigators seeking to perform high-precision in vitro or animal studies, identifying verified research-grade DSIP requires rigorous quality metrics, including analytical HPLC validation and lot-specific endotoxin testing.
Delta-Sleep Inducing Peptide (DSIP) is an amphiphilic nonapeptide widely evaluated in preclinical literature for its capacity to modulate slow-wave delta EEG rhythms and stress-axis signaling. For investigators seeking to perform high-precision in vitro or animal studies, identifying verified research-grade DSIP requires rigorous quality metrics, including analytical HPLC validation and lot-specific endotoxin testing.
When evaluating options for the purchase or sourcing of DSIP (often queried in international research literature as 'achat DSIP'), investigators must prioritize analytical purity, sequence confirmation, and strict batch-to-batch consistency. DSIP is a synthetic nonapeptide with the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. In non-human animal models and in vitro cell culture systems, DSIP is primarily evaluated for its capacity to induce high-voltage slow-wave delta activity during EEG monitoring and to stabilize central stress-axis activity.
To ensure reproducible experimental outcomes, laboratories sourcing the DSIP research peptide must mandate full chemical documentation. This includes lot-specific High-Performance Liquid Chromatography (HPLC) chromatograms confirming a purity profile of ≥98%, alongside Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF) or Liquid Chromatography-Mass Spectrometry (LC-MS) to verify precise molecular mass. PX1 Research provides fully documented, USA-manufactured DSIP synthesized in ISO 17025 accredited facilities for dedicated laboratory and preclinical research use.
First isolated in 1977 by Schoenenberger and Monnier from the cerebral venous blood of rabbits during induced slow-wave sleep, DSIP represents a unique endogenous regulatory peptide. Structurally, it is an unmodified nonapeptide with a molecular weight of 848.81 g/mol. Unlike many peptide hormones that possess terminal amidation or cyclization, DSIP exists in a free linear conformation with exposed N-terminal tryptophan and C-terminal glutamic acid residues.
Because of its amphiphilic structure, DSIP displays unique solubility characteristics across aqueous laboratory buffers and hydrophobic membrane environments. Preclinical literature documents its ability to cross the blood-brain barrier via passive diffusion and specialized carrier-mediated transport mechanisms, making it a critical compound of interest in neurochemical research. Scholars investigating neuroendocrine signal transduction can review detailed structural data across our comprehensive research peptides library.
The primary locus of DSIP investigation in neurophysiology centers on its influence over slow-wave (delta) sleep patterns. Preclinical electroencephalographic (EEG) studies in rodent and rabbit models indicate that low-dose systemic or central administration of DSIP increases the power density and total duration of delta-frequency activity (0.5 to 4.0 Hz) without disrupting REM sleep cycles or causing profound sedation.
In vitro electrophysiological assays demonstrate that DSIP interacts with central GABAergic pathways and modulates NMDA receptor activity. Preclinical data suggest that DSIP does not bind directly to classical benzodiazepine sites; rather, it acts as an allosteric modulator of synaptic plasticity, attenuating neuronal hyperexcitability during cellular stress. This distinct mechanism sets DSIP apart from conventional central nervous system depressants evaluated in neuropharmacology.
Beyond its direct EEG actions, animal studies suggest that DSIP exerts a broad protective effect against environmental and physiological stressors. In preclinical rodent models subjected to acute emotional or oxidative stress, DSIP administration attenuated hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis.
Specifically, in vitro pituitary cell cultures and in vivo plasma assays demonstrate that DSIP regulates basal and stress-induced adrenocorticotropic hormone (ACTH) and corticosterone secretion. Furthermore, research models show that DSIP can suppress basal luteinizing hormone (LH) release while maintaining somatotrophic tone, highlighting its role as a multifaceted neuroendocrine regulator during physiological rest and cellular recovery phases.
When designing neurological or restorative research protocols, investigators frequently compare DSIP to other regulatory peptides targeting central stress pathways, circadian rhythms, or neuroendocrine maintenance. Placing DSIP within its broader peptide class helps clarify its specific receptor interactions and experimental utility.
For example, while DSIP modulates delta-wave EEG rhythms and HPA-axis activation, the Epitalon peptide is primarily investigated for its pineal-gland regulation and telomerase-induction properties in cellular aging models. Similarly, researchers evaluating anxiety-like behaviors and neuroprotective cascades often compare DSIP against the Selank research compound and the synthetic neurotrophic agent Semax peptide. Unlike Selank and Semax, which predominantly act on enkephalinase inhibition and BDNF expression respectively, DSIP displays a preferential affinity for modulating fundamental slow-wave sleep architecture and acute stress response pathways. A full overview of these regulatory agents can be explored in our all research peptides catalog.
Achieving consistent results in laboratory experiments requires standardized handling and reconstitution methodologies. DSIP is supplied as a lyophilized, sterile cake that must be reconstituted using aseptic techniques inside a calibrated laminar flow hood to prevent microbial contamination.
Standard laboratory protocols utilize sterile 0.9% sodium chloride injection or bacteriostatic water containing 0.9% benzyl alcohol as the primary diluent. Gently swirling the vial without vigorous agitation ensures complete dissolution of the peptide matrix without inducing mechanical shearing. For long-term cell culture or enzymatic assays requiring serum-free conditions, sterile phosphate-buffered saline (PBS, pH 7.4) may be utilized. Reconstituted solution aliquots should be prepared immediately to minimize repeated freeze-thaw cycles, which degrade peptide integrity.
Lyophilized DSIP exhibits excellent chemical stability when stored under controlled environmental conditions. Unopened vials should be stored at -20°C for short-term projects (up to 12 months) or at -80°C for extended archival storage. Protection from direct light exposure is critical due to the photosensitive tryptophan residue located at the N-terminus of the molecule.
Once reconstituted into an aqueous medium, DSIP stability decreases significantly over time. Solution aliquots maintain optimal chemical stability for up to 14 days when refrigerated at 2°C to 8°C. If working solutions must be kept for longer periods, store individual aliquots at -20°C or -80°C and thaw immediately prior to assay execution. Avoid repeated thermal cycling, as freeze-thaw events induce protein aggregation and cleavage of the peptide backbone.
In modern peptide research, analytical verification is mandatory to eliminate confounding experimental variables caused by synthetic impurities or incorrect sequences. Sourcing high-purity DSIP demands access to comprehensive, lot-specific Certificates of Analysis (COAs) generated by independent ISO 17025 accredited testing facilities.
Quality verification relies on Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to establish purity levels. Chromatographic peaks should confirm a primary compound purity exceeding 98.0%, with residual trifluoroacetic acid (TFA) salts and truncated peptide fragments minimized. Electrospray Ionization Mass Spectrometry (ESI-MS) or MALDI-TOF must simultaneously confirm a single observed mass peak matching the theoretical monoisotopic mass of 848.81 Da.
Bacterial endotoxins (lipopolysaccharides, or LPS) present a severe confounding variable in cell culture and animal model studies. Presence of endotoxins in research compounds can trigger non-specific inflammatory signaling, cytokine release, and altered neuronal activity, masking the true physiological actions of the target peptide.
PX1 Research subjects every production lot of DSIP to rigorous Chromogenic Recombinant Factor C (rFC) or Limulus Amebocyte Lysate (LAL) testing. To meet research-grade thresholds for delicate neurobiological assays, endotoxin levels are verified below strict limits (<0.5 EU/mg). This rigorous screening ensures that observed cellular responses are attributable solely to the bioactivity of DSIP, rather than immunological artifacts introduced by reagent contamination.
Acquiring DSIP for institutional research requires choosing a reliable supply partner committed to manufacturing compliance and rapid delivery. Laboratories operating under tight project timelines cannot afford delays caused by international customs holds or unverified secondary distributors.
PX1 Research manufactures all research peptides in compliant USA facilities under stringent quality control protocols. Every shipment originates directly from our centralized fulfillment centers in California and Arizona, offering same-day dispatch for orders finalized before standard afternoon cutoffs (Monday through Friday). Principal investigators managing high-throughput laboratories can also establish a bulk research account to lock in batch consistency across multi-phase study designs.
What does the query 'achat dsip' refer to in research literature?
The term 'achat dsip' originates from international research inquiries (specifically French-language searches for purchasing DSIP) seeking suppliers of high-purity, research-grade Delta-Sleep Inducing Peptide for non-human laboratory research.
What is the sequence and molecular weight of DSIP?
DSIP (Delta-Sleep Inducing Peptide) is a synthetic nonapeptide with the linear sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and a molecular weight of 848.81 g/mol.
What primary mechanisms are studied with DSIP in animal models?
Preclinical studies investigate DSIP for its ability to induce slow-wave delta EEG activity, reduce HPA-axis hyperactivation under stress, and modulate central GABA and glutamate neurotransmission.
How should lyophilized DSIP be stored upon delivery?
Unopened, lyophilized DSIP vials should be stored protected from light at -20°C for short-term stability or -80°C for long-term storage to prevent degradation of sensitive residues.
What solvent is recommended for reconstituting DSIP for in vitro assays?
For standard laboratory procedures, DSIP is typically reconstituted in sterile 0.9% sodium chloride, 0.9% benzyl alcohol bacteriostatic water, or sterile phosphate-buffered saline (PBS, pH 7.4).
What documentation proves the purity of PX1 Research DSIP?
Every lot of DSIP from PX1 Research is supplied with an independent ISO 17025 third-party Certificate of Analysis (COA) detailing RP-HPLC purity (≥98%), mass spectrometry identity verification, and LAL endotoxin testing.
What is the endotoxin limit for PX1 Research DSIP?
PX1 Research enforces strict endotoxin safety thresholds, testing every lot to ensure levels remain below 0.5 EU/mg to prevent immune activation artifacts in sensitive cell culture or animal assays.
Does DSIP act as a direct sedative or GABAA agonist?
Preclinical electrophysiological data indicate that DSIP does not act as a direct GABAA receptor agonist or classic central sedative; rather, it functions as a neuromodulator of sleep architecture and stress pathways.
How fast does PX1 Research ship laboratory peptide orders?
PX1 Research dispatches orders same-day Monday through Friday from our facility hubs in California and Arizona, ensuring fast domestic transit for time-sensitive laboratory research.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.